O
CORT icon

OppenheimerFunds’s Corcept Therapeutics CORT Stock Holding History

OppenheimerFunds’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$130K Buy
+11,079
New +$138K ﹤0.01% 1732
2018
Q1 		– Sell
-12,716
Closed -$230K – 1792
2017
Q4 		$230K Buy
+12,716
New +$230K ﹤0.01% 1780

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds's CORT Position: Q1 2019 in Review

OppenheimerFunds opened a new position in Corcept Therapeutics (CORT) in Q1 2019: 11,079 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #1732 among its holdings. This is a return to the name: OppenheimerFunds previously reported a position in CORT as recently as Q4 2017.

OppenheimerFunds first reported a position in CORT in Q4 2017 and has held it in 2 quarters since. The position peaked at $230K in Q4 2017. 208 funds tracked by Wall St. Rank hold CORT as of Q1 2019.

  • OppenheimerFunds held 11,079 shares of Corcept Therapeutics worth $130K as of Q1 2019.
  • Corcept Therapeutics was a new OppenheimerFunds position in Q1 2019.
  • Corcept Therapeutics made up ﹤0.01% of OppenheimerFunds's portfolio in Q1 2019, its #1732 holding.
  • OppenheimerFunds first reported a position in Corcept Therapeutics in Q4 2017 and has held it in 2 quarters since.
  • OppenheimerFunds's Corcept Therapeutics position peaked at $230K in Q4 2017.
  • 208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.